---

Discussion

Priya Merlan:

They amplify signals involved in glucose regulation, appetite and satiety. Semaglutide is sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Wegovy is also approved for certain adults with overweight or obesity and established cardiovascular disease to reduce the risk of major cardiovascular events. Tirzepatide is sold as Mounjaro for diabetes and Zepbound for chronic weight management. Randomized trials show substantial average weight loss when medication is combined with lifestyle support and medical follow-up. But average is important: a trial result describes a group, not a guarantee for one person.

Priya Merlan:

The benefit is not only a number on a scale. Trials generally find better physical functioning and weight-related quality of life. In SURMOUNT-1, people losing at least 20 percent of their weight had the largest improvements, including a 24.7-point gain on the study's weight-related quality-of-life scale. A semaglutide review, however, found statistically significant but modest average improvements that did not reach established minimally important thresholds. Some patients may feel transformed; group averages cannot predict that experience for everyone.

Red Velhouse:

And the lived experience includes both benefit and burden. Kate, what does treatment cost for the person trying to stay on it?

Kate Burvish:

The range is wide. An eligible commercially insured patient may have a copay as low as 25 dollars a month through a manufacturer program, but that is not a universal price. NovoCare lists 199 dollars a month for new self-paying Wegovy patients for the first two monthly fills of certain doses, then 349 dollars; a higher-dose offer is listed at 399 dollars. Older comparisons put major GLP-1 drugs at roughly 936 to 1,349 dollars a month before insurance, rebates or coupons. Whatever the channel, this is a recurring expense, not a one-time purchase.

Priya Merlan:

And cost is only one part of tolerability. Common adverse effects include nausea, vomiting, diarrhea, constipation and abdominal discomfort. The U.S. Food and Drug Administration, or FDA, also identifies less common serious risks, including dehydration-related kidney injury, gallbladder disease, pancreatitis, allergic reactions and aspiration during anesthesia. Some people tolerate treatment well and report better appetite control and mobility. Others stop because side effects, cost or limited benefit outweigh the gains for them.

Red Velhouse:

Do we know whether most patients think those gains are worth the price?

Priya Merlan:

No definitive national percentage answers that question. Qualitative studies find people describing improved mobility, appetite control and health as life-changing, alongside others reporting nausea, stigma, weak support or interrupted access. One willingness-to-pay estimate was about 30 dollars a month, far below many branded direct-pay prices, but hypothetical answers depend on the question and the patient's illness. The evidence supports real benefit for many users, not a universal judgment that the benefit is worth any price.

Kate Burvish:

Affordability data make the distinction clear. In a 2024 survey by KFF, formerly known as the Kaiser Family Foundation, 54 percent of adults who had ever taken a GLP-1 drug said it was difficult to afford, including 22 percent who called it very difficult. Among insured users, 53 percent still reported difficulty. A patient can value a medicine and still be unable to sustain it.

Red Velhouse:

That sustainability question matters because stopping may reverse some of the progress. What happens when treatment ends?

Priya Merlan:

In the STEP 1 extension, people who stopped semaglutide regained a substantial amount of the weight they had lost, and some cardiometabolic measures moved toward baseline. That does not make treatment futile. It means clinicians and patients should discuss whether treatment is intended to continue, what happens if coverage ends and what maintenance strategy is available. An interruption changes the course of care, not merely the prescription.

Kate Burvish:

This is where the payer calculation becomes difficult. The drug cost arrives immediately, while a prevented complication may occur years later—or may never occur for that individual. A lifetime JAMA Health Forum model projected health and productivity benefits, but high medication costs produced estimated incremental cost-effectiveness ratios of about 197,000 dollars per quality-adjusted life-year, or QALY, for tirzepatide and 468,000 dollars per QALY for semaglutide. An analysis from the National Bureau of Economic Research, or NBER, found no reduction in downstream medical spending through 60 months, despite lower spending on some other medicines. A long-term model and a five-year claims result are answering different questions.

Ann Tofado:

There is also a political and institutional mismatch. The employer or insurer paying this year's pharmacy bill may change plans before future benefits appear. A commercial insurer may pay while a later employer, Medicare or Medicaid program receives savings. Patients may still gain mobility, fewer missed workdays or lower cost sharing even when the original payer does not break even. That makes a simple promise of budget savings politically attractive but economically difficult to prove.

Kate Burvish:

The underlying burden explains the interest. The Centers for Disease Control and Prevention, or CDC, estimates that obesity accounted for about 173 billion dollars in direct annual medical costs for U.S. adults in 2019, with excess costs estimated at 1,861 dollars per adult with obesity and 3,097 dollars for severe obesity. But those are population-level burdens, not the amount a GLP-1 prescription automatically saves. Cost-effective, meaning valuable relative to a stated threshold, is not the same as cost-saving, meaning total spending falls.

Red Velhouse:

And access determines who can receive even the treatment shown in trials. Ann, how are governments and plans handling that?

Ann Tofado:

Unequal access is built into the rules. As of July 2024, KFF reported that only 13 state Medicaid fee-for-service programs covered GLP-1 drugs for obesity treatment. Plans may impose body-mass-index or comorbidity thresholds, prior authorization, step therapy, lifestyle requirements or continuation documentation. Medicare generally has not covered obesity drugs through its ordinary Part D prescription-drug benefit solely for weight loss, although coverage can apply for another indication. The Centers for Medicare and Medicaid Services, or CMS, has pursued demonstration and voluntary approaches, including the BALANCE Model, rather than immediately making universal coverage permanent. That lets policymakers test cost and access while limiting political exposure.

Priya Merlan:

Supply and product quality add another layer. Compounded semaglutide and tirzepatide are not approved by the Food and Drug Administration and are not reviewed before marketing in the same way approved products are. The FDA has reported dosing errors and adverse events associated with compounded versions. Patients need to know who prescribed the medicine, what dose they received and what follow-up is available. A prescription that cannot be refilled, monitored or tolerated is not the same intervention studied in a trial.

Ann Tofado:

That creates a regulatory fault line. Patients and telehealth companies emphasize affordability and access; regulators emphasize approval status, quality control and dosing safety. Even when shortages are resolved, affordability pressure remains. Policymakers must address safety without treating a warning as a solution to unequal access.

Kate Burvish:

Competition may eventually help. Novo Nordisk and Eli Lilly currently dominate, competing through supply, prices, delivery devices, direct-pay channels and new formulations. More entrants could improve access, but patents, manufacturing limits and strong demand may delay savings. Household spending may also shift: one transaction-data analysis found grocery spending about 5.3 percent lower within six months among households with a GLP-1 user. That is a modest, early association—not proof that treatment pays for itself. Families may continue buying for other members or spend more on protein, produce, supplements or prepared foods.

Red Velhouse:

So the central uncertainty is not whether these medicines can work. It is who benefits, who pays and for how long.

Priya Merlan:

For patients, success means more than an average trial result. Can they obtain the next dose, manage side effects, receive counseling and continue when treatment is clinically appropriate? Quality-of-life scores matter, but so does the person's own judgment about mobility, daily activity, appetite, social life and cost.

Red Velhouse:

GLP-1 medicines combine meaningful medical benefits with unresolved economic and political questions. Trials support average weight loss, improved physical functioning and selected cardiovascular and metabolic benefits, but individual results, tolerability and persistence vary. Prices range from eligible commercial copays to direct-pay offers of several hundred dollars, with older list-price comparisons much higher. Some households may spend less on groceries, but early evidence does not show that food savings routinely finance treatment. Obesity-related costs are large, yet models and claims studies disagree about whether the payer that pays now will break even later. Coverage rules, insurance changes and public demonstrations determine who receives continuous treatment, while compounded products raise separate safety questions. The key issue is not simply whether these medicines work. It is whether patients can sustain them, whether the benefits feel worth the burden, and whether the people or institutions paying for treatment receive enough value to justify the cost. Sources and references for this discussion are available with the episode at Factolio.com.

---

Sources and References

These sources supported the factual material used in this discussion. Factolio’s panel discussion is AI-generated from researched evidence and is written in original language.

1. U.S. Food and Drug Administration — Wegovy prescribing information and safety information (PRIMARY)
2. Journal of General Internal Medicine / PMC — Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: a national survey (DATA)
3. KFF — KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs (DATA)
4. KFF — Results from an Annual Medicaid Budget Survey for State Fiscal Years 2024 and 2025 (DATA)
5. KFF — 2024 Employer Health Benefits Survey (DATA)
6. NovoCare — Savings Offer Program for Wegovy (PRIMARY)
7. Associated Press — Wegovy and Zepbound prices fall, but access to the obesity drugs still isn't guaranteed (NEWS)
8. Eli Lilly — Authentic Zepbound shipped through LillyDirect (PRIMARY)
9. Associated Press — Patients struggle with lack of consistent coverage for popular weight-loss drugs (NEWS)
10. Centers for Disease Control and Prevention — Consequences of Obesity (PRIMARY)
11. JAMA Health Forum — Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults (PRIMARY)
12. National Bureau of Economic Research — Do GLP-1 Medications Pay for Themselves? (PRIMARY)
13. Cornell Chronicle — Ozempic is changing the foods Americans buy (NEWS)
14. PwC — GLP-1 consumer trends (ANALYSIS)
15. Obesity journal / PMC — Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from SURMOUNT-1 (PRIMARY)
16. Systematic review and meta-analysis / PMC — The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity (PRIMARY)
17. JAMA Network Open — Patient Experiences With GLP-1 Receptor Agonists (PRIMARY)
18. Systematic review / PMC — Patients’ experiences with GLP1-RAs – a systematic review (PRIMARY)
19. Systematic review — Patients’ experiences with GLP1-RAs – discussion of willingness-to-pay evidence (ANALYSIS)